EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)

Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT

Andrew J Pellatt iD, Alisha Bent, Nicholas Hornstein, Christine Parseghian iD, Ryan Huey iD, Kanwal Raghav iD, Van Morris iD, Michael Overman iD, Pia Morelli, Jason Willis iD, Phat Le iD, John Paul Shen iD und 9 weitere

JCO Precision Oncology · 2025-07 · (9)

DOI: 10.1200/po-25-00142 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift JCO Precision Oncology, 2025-07. Verfasst von Andrew J Pellatt und 20 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Intermountain Health, Salt Lake City, UT. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Trifluridine, Uracil, Circulating Tumor DNA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To determine whether treatment with TAS-102 can induce circulating tumor DNA (ctDNA) clearance at 6 months and delay/prevent disease recurrence in colorectal cancer (CRC) patients with ctDNA-defined minimal residual disease (MRD) after completion of adjuvant therapy. PATIENTS AND METHODS This was a single-arm, single-institution, phase II study. Fifteen patients with stage II to IV CRC and ctDNA-defined MRD after curative-intent therapy and adjuvant chemotherapy were enrolled prospectively. Participants received 6 months of therapy with TAS-102 35 mg/m 2 twice a day on days 1-5 and 8-12 of each 28-day cycle. Disease recurrence was monitored every 3 months with ctDNA and cross-sectional imaging. For comparison, 30 patients matched for key variables who received standard of care were retrospectively identified for a synthetic control (SC) cohort. The primary end point was 6-month ctDNA clearance. Secondary end points included 3-month ctDNA clearance, disease-free survival (DFS), and safety. RESULTS Among 15 patients enrolled, median age was 60.2 years (range, 37-73) and 80% were stage IV with an average of 2.1 lines of previous therapy (range, 1-3). At 3 and 6 months, respectively, seven (47%) and five (36%) patients had ctDNA clearance. In the SC, two patients (6.7%) had spontaneous ctDNA clearance at 3 months ( P = .0034) sustained at 6 months ( P = .025). Among patients receiving TAS-102, nine patients had radiographic recurrence with a median DFS of 9.4 months compared with 28 patients in the SC with radiographic recurrence and a median DFS of 5.75 months ( P = .03). CONCLUSION Additional treatment with TAS-102 after adjuvant chemotherapy in CRC patients with ctDNA-defined MRD can induce ctDNA clearance but this may be transient without long-term cures.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsTrifluridineUracilCirculating Tumor DNANeoplasm, ResidualHumansMiddle AgedMaleFemaleAgedDrug CombinationsChemotherapy, AdjuvantThyminePyrrolidinesAdultOligonucleotidesNeoplasm Recurrence, Local

Substanzen

Trifluridinetrifluridine tipiracil drug combinationUracilCirculating Tumor DNADrug CombinationsThyminePyrrolidinesOligonucleotides

Autor:innen und Institutionen

  • Medical Oncology, Intermountain Health, Salt Lake City, UT.
  • Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Northwell, New Hyde Park, NY.
  • Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Andrew J Pellatt, Christine Parseghian, Ryan Huey, Kanwal Raghav, Van Morris, Michael Overman, Jason Willis, Phat Le, John Paul Shen, Bryan Kee, Victoria Higbie, Kathryn Aziz, Ryan Sun, Scott Kopetz, Arvind Dasari

Förderung

  • NCI NIH HHS

Zitieren

APA

Pellatt, A. J., Bent, A., Hornstein, N., Parseghian, C., Huey, R., Raghav, K., Morris, V., Overman, M., Morelli, P., Willis, J., Le, P., Shen, J. P., Kee, B., Eluri, M., Higbie, V., Alfaro-Munoz, K., Aziz, K., Kell, R., Sun, R., …, & Dasari, A. (2025). Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT. JCO Precision Oncology. https://doi.org/10.1200/po-25-00142

Vancouver

Pellatt AJ, Bent A, Hornstein N, Parseghian C, Huey R, Raghav K, et al. Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT. JCO Precision Oncology. 2025. doi:10.1200/po-25-00142

BibTeX
@article{Pellatt2025,
  author = {Pellatt, Andrew J and Bent, Alisha and Hornstein, Nicholas and Parseghian, Christine and Huey, Ryan and Raghav, Kanwal and Morris, Van and Overman, Michael and Morelli, Pia and Willis, Jason and Le, Phat and Shen, John Paul and Kee, Bryan and Eluri, Madhulika and Higbie, Victoria and Alfaro-Munoz, Kristin and Aziz, Kathryn and Kell, Robert and Sun, Ryan and Kopetz, Scott and Dasari, Arvind},
  title = {Phase II Trial of TAS-102 in Colorectal Cancer Patients With Circulating Tumor DNA-Defined Minimal Residual Disease After Adjuvant Therapy: INTERCEPT-TT},
  journal = {JCO Precision Oncology},
  year = {2025},
  number = {9},
  doi = {10.1200/po-25-00142}
}
Kostenlos starten →